AURORA, Colo.--(BUSINESS WIRE)--Vitro Diagnostics, Inc. (OTCBB:VODG), dba Vitro Biopharma, announced the initial distribution of stem cell-derived human beta islets to prospective customers. This was a condition to the exercise of warrants held by a group of private investors that will result in an additional infusion of capital into the Company. The distribution was made with the goal of stimulating sales of the Company’s stem cell-derived products to these prospective customers.
